Companies: Nektar Therapeutics, Ampersand Capital Partners
Drugs: REZPEG, amphotericin B
Nektar Therapeutics pipeline update: REZPEG, amphotericin B and UK site changes
100% citation coverage2 regulatory sources1 peer-reviewed sources
Nektar Therapeutics’ pipeline remains centered on REZPEG, with active Phase 2 programs in atopic dermatitis and alopecia areata and a completed SLE study. The company also has an amphotericin B-linked program context and recent business changes that matter for BD teams and investors.
Intelligence Snapshot
Executive Summary
REZPEG is in active Phase 2 development for atopic dermatitis and alopecia areata, with a completed Phase 2 lupus trial providing clinical breadth.
Key Insights
-
REZPEG is a regulatory T cell-selective interleukin-2 receptor agonist , targeting immune…
REZPEG is a regulatory T cell-selective interleukin-2 receptor agonist , targeting immune dysfunction in inflammatory skin and systemic conditions.
-
Ampersand Capital Partners acquired Nektar's PEGylation reagent supply business and…
Ampersand Capital Partners acquired Nektar's PEGylation reagent supply business and commercial-scale manufacturing facility .
-
Nektar shares fell amid a broad market sell-off triggered by Broadcom's AI guidance miss…
Nektar shares fell amid a broad market sell-off triggered by Broadcom's AI guidance miss , not a standalone pipeline or regulatory event.
Market Impact
| Regulatory | medium |
|---|---|
| Commercial | medium |
| Competitive | high |
| Investment | medium |
Loading intelligence…
Quick Answer
Key Questions
- Why did Nektar Therapeutics stock drop?
- Who bought Nektar?
- What are NKTR's future prospects?
- Is REZPEG a regulatory T cell therapy?
- What indications is REZPEG being studied in?
Executive Scorecard
Heuristic scores · directional, not investment adviceRegulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for REZPEG.
Unlock full calendar →Nektar Therapeutics UK Limited pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Contents14 sections
Nektar Therapeutics pipeline update: REZPEG, amphotericin B and recent business changes
Nektar Therapeutics is advancing REZPEG in active Phase 2 programs for atopic dermatitis and alopecia areata, with a completed Phase 2 systemic lupus erythematosus study. Separately, FDA label data documents amphotericin B regulatory indications; available filings do not describe a current Nektar-owned amphotericin B development program. Recent business changes also matter for BD teams and investors.
IntelligenceRegulatory Impact
FDA and EMA decisions frame this story. Regulatory relevance is medium for this topic, with REZPEG and amphotericin B most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.
Key Takeaways
- REZPEG is in active Phase 2 development for atopic dermatitis and alopecia areata, with a completed Phase 2 systemic lupus erythematosus trial (NCT04433585).
- REZPEG is a regulatory T cell-selective interleukin-2 receptor agonist, targeting immune dysfunction in inflammatory skin and systemic conditions.
- Ampersand Capital Partners acquired Nektar's PEGylation reagent supply business and commercial-scale manufacturing facility.
- Nektar shares fell amid a broad market sell-off triggered by Broadcom's AI guidance miss, not a standalone pipeline or regulatory event.
IntelligenceCompetitive Intelligence
Competitive pressure is high. Nektar Therapeutics and Ampersand Capital Partners reshape positioning, formulary leverage, and partnership options. Benchmark pipeline differentiation and regional market access assumptions against this development.
What is Nektar's current development picture?
Nektar Therapeutics' most decision-relevant pipeline asset is REZPEG, a regulatory T cell-selective interleukin-2 receptor agonist. The company is advancing the program across multiple indications in autoimmune and inflammatory disease.
Two Phase 2b studies are currently active. NCT06136741 is evaluating REZPEG in moderate-to-severe atopic dermatitis, while NCT06340360 (Rezolve AA) is studying the drug in severe to very severe alopecia areata. Both trials are listed as active but not recruiting.
A completed Phase 2 systemic lupus erythematosus trial (NCT04433585) is listed alongside the active atopic dermatitis trial (NCT06136741) and alopecia areata trial (NCT06340360).
IntelligenceMarket Signals
Commercial pull is medium and investment relevance medium for this topic. Expect implications for pricing, access, and launch sequencing.
Amphotericin B: regulatory context
Amphotericin B liposome for injection is FDA-indicated for empirical therapy for presumed fungal infection in febrile, neutropenic patients. The drug is also approved for treatment of cryptococcal meningitis in HIV-infected patients and refractory fungal infections caused by Aspergillus, Candida, and Cryptococcus species.
Newer antifungal candidates are being studied in Phase 2 trials for invasive mould infection, with amphotericin B used in comparative studies. Nektar's specific role in amphotericin B development is not detailed in available filings.
IntelligenceStrategic Takeaways
REZPEG is in active Phase 2 development for atopic dermatitis and alopecia areata, with a completed Phase 2 lupus trial providing clinical breadth. REZPEG is a regulatory T cell-selective interleukin-2 receptor agonist , targeting immune dysfunction in inflammatory skin and systemic conditions. Ampersand Capital Partners acquired Nektar's PEGylation reagent supply business and commercial-scale manufacturing facility
Strategic asset sale and operating implications
Ampersand Capital Partners acquired Nektar's PEGylation reagent supply business and related commercial-scale manufacturing facility. This transaction represents a divestiture of manufacturing and supply-chain infrastructure.
For BD and investor teams, the deal signals a shift in Nektar's operating mix. The company is concentrating on pipeline development and clinical programs rather than maintaining vertically integrated manufacturing and reagent supply operations.
IntelligenceEvidence Quality
Grounded in 2 regulatory sources and 1 peer-reviewed source.
Market context: stock performance and macro drivers
Nektar shares fell amid a broad market sell-off triggered by Broadcom's AI guidance miss, which triggered a sector-wide retreat from technology and risk assets. This decline reflects macro equity volatility rather than a company-specific clinical setback or regulatory action.
For analysts and portfolio managers, distinguishing macro-driven price action from pipeline fundamentals is critical. Nektar's active Phase 2 programs in atopic dermatitis and alopecia areata remain ongoing; the stock movement reflects the broader market sell-off rather than a change in the company's development status.
What to watch next
The immediate focus for Nektar is data readouts from the two active Phase 2b REZPEG studies in atopic dermatitis and alopecia areata. Both trials are listed as active but not recruiting. Data from these studies will inform whether Nektar proceeds with further development in these indications.
The completed lupus trial provides context for understanding REZPEG's activity across disease types. Atopic dermatitis and alopecia areata remain the active development programs tracked on ClinicalTrials.gov.
Drug Snapshot
| Drug | amphotericin B |
|---|---|
| Generic name | AMPHOTERICIN B |
| Drug class | Lipid-based Polyene Antifungal [EPC] |
| Manufacturer | Sun Pharmaceutical Industries, Inc. |
| Route | INTRAVENOUS |
| Indication | INDICATIONS AND USAGE Amphotericin B liposome for injection is indicated for the following: Empirical therapy for presumed fungal infection in febrile, neutropenic patients. Treatment of Cryptococcal Meningitis in HIV-infected patients (see DESCRIPTION OF CLINICAL STUDIES) . Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate. Treatmen |
Regulatory Summary
- Approved indication: INDICATIONS AND USAGE Amphotericin B liposome for injection is indicated for the following: Empirical therapy for presumed fungal infection in febrile, neutropenic patients. Treatment of Cryptococcal Meningitis in HIV-infected patients (see DESCRIPTION OF CLINICAL STUDIES) . Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate. Treatmen
- amphotericin B is_class Lipid-based Polyene Antifungal [EPC]
- Sun Pharmaceutical Industries, Inc. develops amphotericin B
Trial Snapshot
| Trial | Title | Status | Phase | Sponsor |
|---|---|---|---|---|
| NCT06136741 | A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis | ACTIVE_NOT_RECRUITING | PHASE2 | Nektar Therapeutics |
| NCT06340360 | A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA) | ACTIVE_NOT_RECRUITING | PHASE2 | Nektar Therapeutics |
| NCT04433585 | A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE) | COMPLETED | PHASE2 | Nektar Therapeutics |
| NCT07215273 | Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy | RECRUITING | PHASE2 | Elion Therapeutics, Inc. |
| NCT06983665 | Human Bioequivalence Study of Liposomal Amphotericin B for Injection | COMPLETED | NA | Sichuan Huiyu Pharmaceutical Co., Ltd |
Timeline
- Active_Not_Recruiting trial NCT06136741 (PHASE2)
- Active_Not_Recruiting trial NCT06340360 (PHASE2)
- Recruiting trial NCT07215273 (PHASE2)
- Not_Yet_Recruiting trial NCT07261150 (PHASE3)
Frequently Asked Questions
Why did Nektar Therapeutics stock drop?
Nektar shares fell amid a broad market sell-off triggered by Broadcom's AI guidance miss, which triggered a sector-wide retreat from technology and risk assets. The decline reflects macro equity volatility, not a company-specific clinical or regulatory event.
Who bought Nektar?
Ampersand Capital Partners acquired Nektar's PEGylation reagent supply business and related commercial-scale manufacturing facility.
What are NKTR's future prospects?
Nektar is evaluating REZPEG, a regulatory T cell-selective interleukin-2 receptor agonist, in Phase 2b for atopic dermatitis and alopecia areata, with a completed Phase 2 study in systemic lupus erythematosus.
Is REZPEG a regulatory T cell therapy?
REZPEG is a regulatory T cell-selective interleukin-2 receptor agonist, designed to modulate immune function in inflammatory and autoimmune conditions.
What indications is REZPEG being studied in?
REZPEG is in active Phase 2b development for atopic dermatitis and alopecia areata. A Phase 2 trial in systemic lupus erythematosus has been completed.
What is amphotericin B indicated for?
Amphotericin B liposome for injection is FDA-indicated for empirical therapy for presumed fungal infection in febrile, neutropenic patients and for treatment of cryptococcal meningitis in HIV-infected patients and refractory fungal infections.
Related profiles
Related coverage
Continue Exploring
Jump into the entities behind this story.
Ask AI About This Topic
Grounded in NovaPharmaNews intelligence. Pick a prompt to start.
Follow REZPEG developments
Get the latest drug approvals, clinical trials, and regulatory updates delivered to your inbox.
- Sources analyzed
- 3
- Evidence strength
- 88/100
- Last verified
- Jun 8, 2026
- AI-assisted review
- Yes
- Editorial review
- Dr. Sarah Chen
High source quality · grounded in cited primary and secondary sources.
This article follows our editorial standards. Report a correction via editorial contact.
